wastewater mapping of toxic medicine in hospital ...cleanmedeurope.org/uploads/parallel sessions...

14
Environmental effective treatment and mapping of toxic medicine in hospital wastewater Thomas Møller Caroline Kragelund Rickers, Kim Sundmark, Henrik Rasmus Andersen, Erik Bundgaard, Alice Toft Christensen, Kai Bester, Christina Sund, Jeanette Dietz Andersen, Karen Klarskov Møller, Niels Møller Jensen, Magnus Christensson, Klaus Litty, Sabine Lindholst

Upload: dinhcong

Post on 30-Mar-2018

223 views

Category:

Documents


5 download

TRANSCRIPT

Page 1: wastewater mapping of toxic medicine in hospital ...cleanmedeurope.org/uploads/Parallel sessions D/D1_Moeller.pdf · Supplier: Krüger, Veolia. Project participants in MERMISS Moving

Environmental effective treatment and mapping of toxic medicine in hospital wastewater

Thomas Møller

Caroline Kragelund Rickers, Kim Sundmark, Henrik Rasmus Andersen, Erik Bundgaard, Alice Toft Christensen, Kai Bester, Christina Sund, Jeanette Dietz Andersen, Karen Klarskov Møller, Niels Møller Jensen, Magnus Christensson, Klaus Litty, Sabine Lindholst

Page 2: wastewater mapping of toxic medicine in hospital ...cleanmedeurope.org/uploads/Parallel sessions D/D1_Moeller.pdf · Supplier: Krüger, Veolia. Project participants in MERMISS Moving

▪ Is it the environmental right thing to treat wastewater locally at the hospital?

▪ Call for a common international list of unwanted pharmaceuticals in the environment

▪ Treatment possibilities

The agenda

Page 3: wastewater mapping of toxic medicine in hospital ...cleanmedeurope.org/uploads/Parallel sessions D/D1_Moeller.pdf · Supplier: Krüger, Veolia. Project participants in MERMISS Moving

More ambulant treatments

▪ Increase of 1/3 from 2007 to 2015

▪ More medicine is discharged from patientsown homes

▪ Removal of pharma from wastewater is relatively expensive▪ Mapping the environmental benefit highly relevant

Page 4: wastewater mapping of toxic medicine in hospital ...cleanmedeurope.org/uploads/Parallel sessions D/D1_Moeller.pdf · Supplier: Krüger, Veolia. Project participants in MERMISS Moving

▪ Only pharmaceuticals exceeding 2% of national consumption.

▪ Based on a danish list contending 42 pharmaceuticals (expanding)

▪ Toxicity in nature based on PNEC.

▪ Precondition: All consumed medicine is disposed directly into the toilet/sewer (conservative estimate)▪ Metabolisation is not in consideration▪ Cocktaileffect is not in consideration▪ Half-life is not in consideration

Mapping of discharge from AUH

Page 5: wastewater mapping of toxic medicine in hospital ...cleanmedeurope.org/uploads/Parallel sessions D/D1_Moeller.pdf · Supplier: Krüger, Veolia. Project participants in MERMISS Moving

Mapping of discharge from AUH

▪ Essential: Mapping is based on numbers from the electronic patient journal (EPJ) and quality assured with data from the pharmacy at Aarhus University Hospital▪ Calculated environmental impact for

▪ Primary sector▪ Secondary sector

▪ 6 drugs in specific implies great environmental impact (98% of the total impact)▪ Mycophenolacid (71% alone), clarithromyzin, sulfamethoxazol,

sertralin, ciprofloxazin and capecitabin

Page 6: wastewater mapping of toxic medicine in hospital ...cleanmedeurope.org/uploads/Parallel sessions D/D1_Moeller.pdf · Supplier: Krüger, Veolia. Project participants in MERMISS Moving

Calculated environmental impact

▪ Significant increase in environmental impact from primary sector (summed PNEC)▪ 2011: 11571▪ 2015: 25897 (124%)

▪ Moderate increase in environmental impact from hospitalized patients (summed PNEC)▪ 2011: 3181▪ 2015: 5092 (60%)

Page 7: wastewater mapping of toxic medicine in hospital ...cleanmedeurope.org/uploads/Parallel sessions D/D1_Moeller.pdf · Supplier: Krüger, Veolia. Project participants in MERMISS Moving

Calculated environmental impact

▪ Impact from primary sector in percentages of total.▪ 2011: 78,4%▪ 2015: 83,6%

Page 8: wastewater mapping of toxic medicine in hospital ...cleanmedeurope.org/uploads/Parallel sessions D/D1_Moeller.pdf · Supplier: Krüger, Veolia. Project participants in MERMISS Moving

▪ Measured concentrations support the calculated concentrations and impact

Calculated and measured concentrations

Pharmaceutical Inlet WWTP

Outlet WWTP

Calculated

µg/l µg/l µg/l

Azithromycin 1,090 0,617 1,71

Carbamazepin 0,129 0,065 2,53

Ciprofloxacin 2,783 0,972 46,50

Clarithromycin 1,603 0,326 13,78

Diclofenac 0,212 0,037 0,19

Ibuprofen 16,300 0,365 87,71

Propranolol 0,243 0,209 0,52

Sulfamethoxazole 1,830 0,785 135,51

Venlafaxine 2,700 1,400 2,23

Page 9: wastewater mapping of toxic medicine in hospital ...cleanmedeurope.org/uploads/Parallel sessions D/D1_Moeller.pdf · Supplier: Krüger, Veolia. Project participants in MERMISS Moving

▪ Time to think, before capital is invested!▪ Risk, that the environmental effect of local treatment fail to materialize.▪ Removal of pharmaceuticals from wastewater is relatively expensive.

Therefore the right placement is important.▪ Mapping of distribution of environmental impact between primary and

secondary sector is important – even crucial.▪ Treatment of all municipal wastewater will of course be more expensive

in total. But if the environmental effect is even bigger, a central treatment at the municipal wastewater treatment plant would be the right strategy.

Conclusions on mapping in Aarhus

Page 10: wastewater mapping of toxic medicine in hospital ...cleanmedeurope.org/uploads/Parallel sessions D/D1_Moeller.pdf · Supplier: Krüger, Veolia. Project participants in MERMISS Moving

MBR versus MBBR

▪ MBR technology working and operationg in full scale at Herlev Hospital, Denmark. ▪ Supplier: Grundfos, BioBooster

▪ MBBR technology still under development in the MERMISS project.▪ Supplier: Krüger, Veolia

Page 11: wastewater mapping of toxic medicine in hospital ...cleanmedeurope.org/uploads/Parallel sessions D/D1_Moeller.pdf · Supplier: Krüger, Veolia. Project participants in MERMISS Moving

Project participants in MERMISS

Page 12: wastewater mapping of toxic medicine in hospital ...cleanmedeurope.org/uploads/Parallel sessions D/D1_Moeller.pdf · Supplier: Krüger, Veolia. Project participants in MERMISS Moving

▪ Moving Bed BioReactor (MBBR)▪ Biological part consists of six reactors

▪ Specialized microorganisms

▪ Subsequent chemical oxidation with ozone▪ Tested at Aarhus University Hospital in 2015

▪ Over a period of 9 months

▪ Is being tested at Herning Vand in 2016▪ Municipal wastewater treatment plant

MBBR technology

Page 13: wastewater mapping of toxic medicine in hospital ...cleanmedeurope.org/uploads/Parallel sessions D/D1_Moeller.pdf · Supplier: Krüger, Veolia. Project participants in MERMISS Moving

▪ MERMISS is now up and running in Herning▪ Treatment of treated wastewater

(post treatment)▪ Mapping the removal of

pharmaceuticals▪ Treatment cost calculation

▪ Benchmark between local treatment at the hospital and centrally at the municipal wastewater treatment plant.

We’ll be wiser in 2017

Page 14: wastewater mapping of toxic medicine in hospital ...cleanmedeurope.org/uploads/Parallel sessions D/D1_Moeller.pdf · Supplier: Krüger, Veolia. Project participants in MERMISS Moving

▪ Questions are of course welcome:

Thomas MøllerEnvironmental Coordinator at Aarhus University [email protected]

Thank you!